TYK2 Inhibition in Paradoxical Psoriasis

Conditions: Psoriasis Interventions: Drug: Deucravacitinib Sponsors: Prof Curdin Conrad; Centre Hospitalier Universitaire Vaudois Not yet recruiting

Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials